Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 621

1.

Survival Outcomes From a Cumulative Analysis of Worldwide Observational Studies on Sequential Use of New Agents in Metastatic Castration-Resistant Prostate Cancer.

Caffo O, Wissing M, Bianchini D, Bergman A, Thomsen FB, Schmid S, Yu EY, Bournakis E, Sella A, Zagonel V, De Giorgi U, Tucci M, Gelderblom H, Galli L, Pappagallo G, Bria E, Sperduti I, Oudard S; CASTOR study investigators.

Clin Genitourin Cancer. 2019 Sep 27. pii: S1558-7673(19)30279-4. doi: 10.1016/j.clgc.2019.09.010. [Epub ahead of print]

PMID:
31767448
2.

Intrigue: Phase III study of ripretinib versus sunitinib in advanced gastrointestinal stromal tumor after imatinib.

Nemunaitis J, Bauer S, Blay JY, Choucair K, Gelderblom H, George S, Schöffski P, Mehren MV, Zalcberg J, Achour H, Ruiz-Soto R, Heinrich MC.

Future Oncol. 2019 Nov 22. doi: 10.2217/fon-2019-0633. [Epub ahead of print]

3.

Home treatment of patients with cancer-associated venous thromboembolism - An evaluation of daily practice.

Hendriks SV, Huisman MV, Eikenboom JCJ, Fogteloo J, Gelderblom H, van der Meer FJM, Stenger WJE, Verschoor AJ, Versteeg HH, Klok FA.

Thromb Res. 2019 Dec;184:122-128. doi: 10.1016/j.thromres.2019.10.031. Epub 2019 Nov 4.

4.

Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study.

Chawla S, Blay JY, Rutkowski P, Le Cesne A, Reichardt P, Gelderblom H, Grimer RJ, Choy E, Skubitz K, Seeger L, Schuetze SM, Henshaw R, Dai T, Jandial D, Palmerini E.

Lancet Oncol. 2019 Dec;20(12):1719-1729. doi: 10.1016/S1470-2045(19)30663-1. Epub 2019 Nov 6.

PMID:
31704134
5.

Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor.

Verspoor FGM, Mastboom MJL, Hannink G, Maki RG, Wagner A, Bompas E, Desai J, Italiano A, Seddon BM, van der Graaf WTA, Blay JY, Brahmi M, Eberst L, Stacchiotti S, Mir O, van de Sande MAJ, Gelderblom H, Cassier PA.

Sci Rep. 2019 Oct 10;9(1):14551. doi: 10.1038/s41598-019-51211-y.

6.

Which Factors Are Associated with Local Control and Survival of Patients with Localized Pelvic Ewing's Sarcoma? A Retrospective Analysis of Data from the Euro-EWING99 Trial.

Andreou D, Ranft A, Gosheger G, Timmermann B, Ladenstein R, Hartmann W, Bauer S, Baumhoer D, van den Berg H, Dijkstra PDS, Dürr HR, Gelderblom H, Hardes J, Hjorth L, Kreyer J, Kruseova J, Leithner A, Scobioala S, Streitbürger A, Tunn PU, Wardelmann E, Windhager R, Jürgens H, Dirksen U; GPOH-Euro-EWING99 consortium.

Clin Orthop Relat Res. 2019 Sep 26. doi: 10.1097/CORR.0000000000000962. [Epub ahead of print]

PMID:
31580267
7.

The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs.

van der Velden DL, Hoes LR, van der Wijngaart H, van Berge Henegouwen JM, van Werkhoven E, Roepman P, Schilsky RL, de Leng WWJ, Huitema ADR, Nuijen B, Nederlof PM, van Herpen CML, de Groot DJA, Devriese LA, Hoeben A, de Jonge MJA, Chalabi M, Smit EF, de Langen AJ, Mehra N, Labots M, Kapiteijn E, Sleijfer S, Cuppen E, Verheul HMW, Gelderblom H, Voest EE.

Nature. 2019 Oct;574(7776):127-131. doi: 10.1038/s41586-019-1600-x. Epub 2019 Sep 30.

PMID:
31570881
8.

Therapeutic Drug Monitoring of Oral Anticancer Drugs: The Dutch Pharmacology Oncology Group-Therapeutic Drug Monitoring Protocol for a Prospective Study.

Groenland SL, van Eerden RAG, Verheijen RB, Koolen SLW, Moes DJAR, Desar IME, Reyners AKL, Gelderblom HJ, van Erp NP, Mathijssen RHJ, Huitema ADR, Steeghs N.

Ther Drug Monit. 2019 Oct;41(5):561-567. doi: 10.1097/FTD.0000000000000654.

PMID:
31568233
9.

High-Dose Chemotherapy Compared With Standard Chemotherapy and Lung Radiation in Ewing Sarcoma With Pulmonary Metastases: Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008.

Dirksen U, Brennan B, Le Deley MC, Cozic N, van den Berg H, Bhadri V, Brichard B, Claude L, Craft A, Amler S, Gaspar N, Gelderblom H, Goldsby R, Gorlick R, Grier HE, Guinbretiere JM, Hauser P, Hjorth L, Janeway K, Juergens H, Judson I, Krailo M, Kruseova J, Kuehne T, Ladenstein R, Lervat C, Lessnick SL, Lewis I, Linassier C, Marec-Berard P, Marina N, Morland B, Pacquement H, Paulussen M, Randall RL, Ranft A, Le Teuff G, Wheatley K, Whelan J, Womer R, Oberlin O, Hawkins DS; Euro-E.W.I.N.G. 99 and Ewing 2008 Investigators.

J Clin Oncol. 2019 Dec 1;37(34):3192-3202. doi: 10.1200/JCO.19.00915. Epub 2019 Sep 25.

PMID:
31553693
10.

Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network.

Frezza AM, Assi T, Lo Vullo S, Ben-Ami E, Dufresne A, Yonemori K, Noguchi E, Siontis B, Ferraro R, Teterycz P, Duffaud F, Ravi V, Vincenzi B, Gelderblom H, Pantaleo MA, Baldi GG, Desar I, Fedenko A, Maki RG, Jones RL, Benjamin RS, Blay JY, Kawai A, Gounder M, Gronchi A, Le Cesne A, Mir O, Czarnecka AM, Schuetze S, Wagner AJ, Adam J, Barisella M, Sbaraglia M, Hornick JL, Meurgey A, Mariani L, Casali PG, Thornton K, Stacchiotti S.

Cancer. 2019 Sep 19. doi: 10.1002/cncr.32508. [Epub ahead of print]

PMID:
31536651
11.

Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses.

Cesne AL, Bauer S, Demetri GD, Han G, Dezzani L, Ahmad Q, Blay JY, Judson I, Schöffski P, Aglietta M, Hohenberger P, Gelderblom H.

BMC Cancer. 2019 Aug 13;19(1):794. doi: 10.1186/s12885-019-5988-3.

12.

Individual risk evaluation for local recurrence and distant metastasis in Ewing sarcoma: A multistate model: A multistate model for Ewing sarcoma.

Bosma SE, Rueten-Budde AJ, Lancia C, Ranft A, Dirksen U, Krol AD, Gelderblom H, van de Sande MAJ, Dijkstra PDS, Fiocco M.

Pediatr Blood Cancer. 2019 Nov;66(11):e27943. doi: 10.1002/pbc.27943. Epub 2019 Aug 6.

PMID:
31389188
13.

Easy-to-use clinical tool for survival estimation in Ewing sarcoma at diagnosis and after surgery.

Bosma SE, Lancia C, Rueten-Budde AJ, Ranft A, Gelderblom H, Fiocco M, van de Sande MAJ, Dijkstra PDS, Dirksen U.

Sci Rep. 2019 Jul 29;9(1):11000. doi: 10.1038/s41598-019-46721-8.

14.

The effect of gastrectomy on regorafenib exposure and progression-free survival in patients with advanced gastrointestinal stromal tumours.

Lubberman FJE, van der Graaf WTA, Xu L, Cleton A, Demetri GD, Gelderblom H, van Erp NP.

Br J Clin Pharmacol. 2019 Oct;85(10):2399-2404. doi: 10.1111/bcp.14061. Epub 2019 Aug 19.

15.

Survival and Cost-Effectiveness of Trabectedin Compared to Ifosfamide Monotherapy in Advanced Soft Tissue Sarcoma Patients.

Verboom MC, Gelderblom H, Kerst JM, Steeghs N, Reyners AKL, Sleijfer S, van der Graaf WTA, van den Hout WB.

Sarcoma. 2019 Jun 2;2019:3234205. doi: 10.1155/2019/3234205. eCollection 2019.

16.

Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial.

Tap WD, Gelderblom H, Palmerini E, Desai J, Bauer S, Blay JY, Alcindor T, Ganjoo K, Martín-Broto J, Ryan CW, Thomas DM, Peterfy C, Healey JH, van de Sande M, Gelhorn HL, Shuster DE, Wang Q, Yver A, Hsu HH, Lin PS, Tong-Starksen S, Stacchiotti S, Wagner AJ; ENLIVEN investigators.

Lancet. 2019 Aug 10;394(10197):478-487. doi: 10.1016/S0140-6736(19)30764-0. Epub 2019 Jun 19.

PMID:
31229240
17.

Reply to C.L. Braal et al, H. Brauch et al, and M.P. Goetz et al.

Guchelaar HJ, Sanchez-Spitman A, Dezentjé V, Böhringer S, Swen J, Neven P, Gelderblom H.

J Clin Oncol. 2019 Aug 1;37(22):1984-1985. doi: 10.1200/JCO.19.00932. Epub 2019 Jun 18. No abstract available.

PMID:
31211601
18.

Method to measure the mismatch between target and achieved received dose intensity of chemotherapy in cancer trials: a retrospective analysis of the MRC BO06 trial in osteosarcoma.

Lancia C, Anninga J, Spitoni C, Sydes MR, Whelan J, Hogendoorn PCW, Gelderblom H, Fiocco M.

BMJ Open. 2019 May 30;9(5):e022980. doi: 10.1136/bmjopen-2018-022980.

19.

The Effect of Using Pazopanib With Food vs. Fasted on Pharmacokinetics, Patient Safety, and Preference (DIET Study).

Lubberman FJE, Gelderblom H, Hamberg P, Vervenne WL, Mulder SF, Jansman FGA, Colbers A, van der Graaf WTA, Burger DM, Luelmo S, Moes DJAR, van Herpen CML, van Erp NP.

Clin Pharmacol Ther. 2019 Nov;106(5):1076-1082. doi: 10.1002/cpt.1515. Epub 2019 Jul 9.

PMID:
31125423
20.

Stromal organization as predictive biomarker for the treatment of colon cancer with adjuvant bevacizumab; a post-hoc analysis of the AVANT trial.

Zunder S, van der Wilk P, Gelderblom H, Dekker T, Mancao C, Kiialainen A, Putter H, Tollenaar R, Mesker W.

Cell Oncol (Dordr). 2019 Oct;42(5):717-725. doi: 10.1007/s13402-019-00449-9. Epub 2019 May 17.

PMID:
31102145
21.

Adjuvant Zoledronic Acid in High-Risk Giant Cell Tumor of Bone: A Multicenter Randomized Phase II Trial.

Lipplaa A, Kroep JR, van der Heijden L, Jutte PC, Hogendoorn PCW, Dijkstra S, Gelderblom H.

Oncologist. 2019 Jul;24(7):889-e421. doi: 10.1634/theoncologist.2019-0280. Epub 2019 Apr 30.

22.

Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients.

van Waalwijk van Doorn-Khosrovani SB, Pisters-van Roy A, van Saase L, van der Graaff M, Gijzen J, Sleijfer S, Hoes LR, van Berge Henegouwen JM, van der Wijngaart H, van der Velden DL, van Werkhoven E, Retel VP, van Harten WH, Huitema ADR, Timmers L, Gelderblom H, Verheul HMW, Voest EE.

Ann Oncol. 2019 May 1;30(5):663-665. doi: 10.1093/annonc/mdz119. No abstract available.

PMID:
31038154
23.

A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic soft-tissue sarcomas.

Jones RL, Chawla SP, Attia S, Schöffski P, Gelderblom H, Chmielowski B, Le Cesne A, Van Tine BA, Trent JC, Patel S, Wagner AJ, Chugh R, Heyburn JW, Weil SC, Wang W, Viele K, Maki RG.

Cancer. 2019 Jul 15;125(14):2445-2454. doi: 10.1002/cncr.32084. Epub 2019 Apr 29.

24.

Surgical outcomes of patients with diffuse-type tenosynovial giant-cell tumours: an international, retrospective, cohort study.

Mastboom MJL, Palmerini E, Verspoor FGM, Rueten-Budde AJ, Stacchiotti S, Staals EL, Schaap GR, Jutte PC, Aston W, Gelderblom H, Leithner A, Dammerer D, Takeuchi A, Thio Q, Niu X, Wunder JS; TGCT Study Group, van de Sande MAJ.

Lancet Oncol. 2019 Jun;20(6):877-886. doi: 10.1016/S1470-2045(19)30100-7. Epub 2019 Apr 24.

PMID:
31029509
25.

18F-FDG PET-CT versus MRI for detection of skeletal metastasis in Ewing sarcoma.

Bosma SE, Vriens D, Gelderblom H, van de Sande MAJ, Dijkstra PDS, Bloem JL.

Skeletal Radiol. 2019 Nov;48(11):1735-1746. doi: 10.1007/s00256-019-03192-2. Epub 2019 Apr 23.

26.

Clinical pharmacokinetics and pharmacogenetics of tamoxifen and endoxifen.

Sanchez-Spitman AB, Swen JJ, Dezentje VO, Moes DJAR, Gelderblom H, Guchelaar HJ.

Expert Rev Clin Pharmacol. 2019 Jun;12(6):523-536. doi: 10.1080/17512433.2019.1610390. Epub 2019 Apr 30. Review.

PMID:
31008668
27.

Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised controlled trial.

Priddy FH, Lewis DJM, Gelderblom HC, Hassanin H, Streatfield C, LaBranche C, Hare J, Cox JH, Dally L, Bendel D, Montefiori D, Sayeed E, Ackland J, Gilmour J, Schnepp BC, Wright JF, Johnson P.

Lancet HIV. 2019 Apr;6(4):e230-e239. doi: 10.1016/S2352-3018(19)30003-7. Epub 2019 Mar 15. Erratum in: Lancet HIV. 2019 Apr 3;:.

28.

Point-of-care HIV RNA testing and immediate antiretroviral therapy initiation in young adults seeking out-patient care in Kenya.

Sanders EJ, Chirro O, Oduor C, Mangi J, Wahome E, Price MA, Gelderblom HC, van der Elst EM, Graham SM.

AIDS. 2019 Apr 1;33(5):923-926. doi: 10.1097/QAD.0000000000002110.

29.

A novel method to address the association between received dose intensity and survival outcome: benefits of approaching treatment intensification at a more individualised level in a trial of the European Osteosarcoma Intergroup.

Lancia C, Anninga JK, Sydes MR, Spitoni C, Whelan J, Hogendoorn PCW, Gelderblom H, Fiocco M.

Cancer Chemother Pharmacol. 2019 May;83(5):951-962. doi: 10.1007/s00280-019-03797-3. Epub 2019 Mar 16.

30.

Challenges of denosumab in giant cell tumor of bone, and other giant cell-rich tumors of bone.

Lipplaa A, Dijkstra S, Gelderblom H.

Curr Opin Oncol. 2019 Jul;31(4):329-335. doi: 10.1097/CCO.0000000000000529.

31.

Association of pazopanib-induced toxicities with outcome of patients with advanced soft tissue sarcoma; a retrospective analysis based on the European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 clinical trials.

Vos M, Sleijfer S, Litière S, Touati N, Duffaud F, van der Graaf WT, Gelderblom H.

Acta Oncol. 2019 Jun;58(6):872-879. doi: 10.1080/0284186X.2019.1581376. Epub 2019 Mar 4.

PMID:
30831041
32.

Impact of Concomitant Administration of Gastric Acid-Suppressive Agents and Pazopanib on Outcomes in Soft-Tissue Sarcoma Patients Treated within the EORTC 62043/62072 Trials.

Mir O, Touati N, Lia M, Litière S, Le Cesne A, Sleijfer S, Blay JY, Leahy M, Young R, Mathijssen RHJ, Van Erp NP, Gelderblom H, Van der Graaf WT, Gronchi A.

Clin Cancer Res. 2019 Mar 1;25(5):1479-1485. doi: 10.1158/1078-0432.CCR-18-2748. Epub 2019 Feb 14.

PMID:
30765389
33.

Predicting Survival in Patients Undergoing Resection for Locally Recurrent Retroperitoneal Sarcoma: A Study and Novel Nomogram from TARPSWG.

Raut CP, Callegaro D, Miceli R, Barretta F, Rutkowski P, Blay JY, Lahat G, Strauss DC, Gonzalez R, Ahuja N, Grignani G, Quagliuolo V, Stoeckle E, De Paoli A, Pillarisetty VG, Nessim C, Swallow CJ, Bagaria S, Canter R, Mullen J, Gelderblom HJ, Pennacchioli E, van Coevorden F, Cardona K, Fiore M, Fairweather M, Gronchi A.

Clin Cancer Res. 2019 Apr 15;25(8):2664-2671. doi: 10.1158/1078-0432.CCR-18-2700. Epub 2019 Feb 5.

PMID:
30723141
34.

HIV virologic failure and its predictors among HIV-infected adults on antiretroviral therapy in the African Cohort Study.

Kiweewa F, Esber A, Musingye E, Reed D, Crowell TA, Cham F, Semwogerere M, Namagembe R, Nambuya A, Kafeero C, Tindikahwa A, Eller LA, Millard M, Gelderblom HC, Keshinro B, Adamu Y, Maswai J, Owuoth J, Sing'oei VC, Maganga L, Bahemana E, Khamadi S, Robb ML, Ake JA, Polyak CS, Kibuuka H.

PLoS One. 2019 Feb 5;14(2):e0211344. doi: 10.1371/journal.pone.0211344. eCollection 2019.

35.

Genetic polymorphisms in ABCG2 and CYP1A2 are associated with imatinib dose reduction in patients treated for gastrointestinal stromal tumors.

Verboom MC, Kloth JSL, Swen JJ, Sleijfer S, Reyners AKL, Steeghs N, Mathijssen RHJ, Gelderblom H, Guchelaar HJ.

Pharmacogenomics J. 2019 Oct;19(5):473-479. doi: 10.1038/s41397-019-0079-z. Epub 2019 Feb 4.

PMID:
30713339
36.

The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial.

Pasquali S, Pizzamiglio S, Touati N, Litiere S, Marreaud S, Kasper B, Gelderblom H, Stacchiotti S, Judson I, Dei Tos AP, Verderio P, Casali PG, Woll PJ, Gronchi A; EORTC – Soft Tissue and Bone Sarcoma Group.

Eur J Cancer. 2019 Mar;109:51-60. doi: 10.1016/j.ejca.2018.12.009. Epub 2019 Jan 25.

PMID:
30690293
37.

Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort.

Smeland S, Bielack SS, Whelan J, Bernstein M, Hogendoorn P, Krailo MD, Gorlick R, Janeway KA, Ingleby FC, Anninga J, Antal I, Arndt C, Brown KLB, Butterfass-Bahloul T, Calaminus G, Capra M, Dhooge C, Eriksson M, Flanagan AM, Friedel G, Gebhardt MC, Gelderblom H, Goldsby R, Grier HE, Grimer R, Hawkins DS, Hecker-Nolting S, Sundby Hall K, Isakoff MS, Jovic G, Kühne T, Kager L, von Kalle T, Kabickova E, Lang S, Lau CC, Leavey PJ, Lessnick SL, Mascarenhas L, Mayer-Steinacker R, Meyers PA, Nagarajan R, Randall RL, Reichardt P, Renard M, Rechnitzer C, Schwartz CL, Strauss S, Teot L, Timmermann B, Sydes MR, Marina N.

Eur J Cancer. 2019 Mar;109:36-50. doi: 10.1016/j.ejca.2018.11.027. Epub 2019 Jan 25.

38.

Tamoxifen Pharmacogenetics and Metabolism: Results From the Prospective CYPTAM Study.

Sanchez-Spitman A, Dezentjé V, Swen J, Moes DJAR, Böhringer S, Batman E, van Druten E, Smorenburg C, van Bochove A, Zeillemaker A, Jongen L, Los M, Neven P, Gelderblom H, Guchelaar HJ.

J Clin Oncol. 2019 Mar 10;37(8):636-646. doi: 10.1200/JCO.18.00307. Epub 2019 Jan 24.

PMID:
30676859
39.

Genome wide association study to identify predictors for severe skin toxicity in colorectal cancer patients treated with cetuximab.

Baas J, Krens L, Bohringer S, Mol L, Punt C, Guchelaar HJ, Gelderblom H.

PLoS One. 2018 Dec 17;13(12):e0208080. doi: 10.1371/journal.pone.0208080. eCollection 2018.

40.

A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy.

Henricks LM, Lunenburg CATC, de Man FM, Meulendijks D, Frederix GWJ, Kienhuis E, Creemers GJ, Baars A, Dezentjé VO, Imholz ALT, Jeurissen FJF, Portielje JEA, Jansen RLH, Hamberg P, Ten Tije AJ, Droogendijk HJ, Koopman M, Nieboer P, van de Poel MHW, Mandigers CMPW, Rosing H, Beijnen JH, van Werkhoven E, van Kuilenburg ABP, van Schaik RHN, Mathijssen RHJ, Swen JJ, Gelderblom H, Cats A, Guchelaar HJ, Schellens JHM.

Eur J Cancer. 2019 Jan;107:60-67. doi: 10.1016/j.ejca.2018.11.010. Epub 2018 Dec 11.

PMID:
30544060
41.

Ototoxicity in locally advanced head and neck cancer patients treated with induction chemotherapy followed by intermediate or high-dose cisplatin-based chemoradiotherapy.

Driessen CML, Leijendeckers J, Snik A, van der Graaf WTA, de Boer JP, Gelderblom H, Kaanders JHAM, Takes R, van Herpen CML.

Head Neck. 2019 Feb;41(2):488-494. doi: 10.1002/hed.25434. Epub 2018 Dec 7.

PMID:
30536479
42.

Diagnostic and Therapeutic Strategies for Fluoropyrimidine Treatment of Patients Carrying Multiple DPYD Variants.

Lunenburg CATC, Henricks LM, van Kuilenburg ABP, Mathijssen RHJ, Schellens JHM, Gelderblom H, Guchelaar HJ, Swen JJ.

Genes (Basel). 2018 Nov 28;9(12). pii: E585. doi: 10.3390/genes9120585.

43.

Prognostic factors for survival in Ewing sarcoma: A systematic review.

Bosma SE, Ayu O, Fiocco M, Gelderblom H, Dijkstra PDS.

Surg Oncol. 2018 Dec;27(4):603-610. doi: 10.1016/j.suronc.2018.07.016. Epub 2018 Jul 30.

44.

Surgical and medical management of small bowel gastrointestinal stromal tumors: A report of the Dutch GIST registry.

Boonstra PA, Steeghs N, Farag S, van Coevorden F, Gelderblom H, Grunhagen DJ, Desar IME, van der Graaf WTA, Bonenkamp JJ, Reyners AKL, van Etten B.

Eur J Surg Oncol. 2019 Mar;45(3):410-415. doi: 10.1016/j.ejso.2018.09.013. Epub 2018 Oct 16.

PMID:
30416078
45.

Influenza vaccination in patients with lung cancer receiving anti-programmed death receptor 1 immunotherapy does not induce immune-related adverse events.

Wijn DH, Groeneveld GH, Vollaard AM, Muller M, Wallinga J, Gelderblom H, Smit EF.

Eur J Cancer. 2018 Nov;104:182-187. doi: 10.1016/j.ejca.2018.09.012. Epub 2018 Oct 24.

PMID:
30368069
46.

Impact of CYP3A4*22 on Pazopanib Pharmacokinetics in Cancer Patients.

Bins S, Huitema ADR, Laven P, Bouazzaoui SE, Yu H, van Erp N, van Herpen C, Hamberg P, Gelderblom H, Steeghs N, Sleijfer S, van Schaik RHN, Mathijssen RHJ, Koolen SLW.

Clin Pharmacokinet. 2019 May;58(5):651-658. doi: 10.1007/s40262-018-0719-5.

47.

Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers.

Lunenburg CATC, Henricks LM, Dreussi E, Peters FP, Fiocco M, Meulendijks D, Toffoli G, Guchelaar HJ, Swen JJ, Cecchin E, Schellens JHM, Gelderblom H.

Eur J Cancer. 2018 Nov;104:210-218. doi: 10.1016/j.ejca.2018.07.138. Epub 2018 Oct 23.

PMID:
30361102
48.

Surrogate endpoints in advanced sarcoma trials: a meta-analysis.

Savina M, Litière S, Italiano A, Burzykowski T, Bonnetain F, Gourgou S, Rondeau V, Blay JY, Cousin S, Duffaud F, Gelderblom H, Gronchi A, Judson I, Le Cesne A, Lorigan P, Maurel J, van der Graaf W, Verweij J, Mathoulin-Pélissier S, Bellera C.

Oncotarget. 2018 Oct 2;9(77):34617-34627. doi: 10.18632/oncotarget.26166. eCollection 2018 Oct 2.

49.

DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.

Henricks LM, Lunenburg CATC, de Man FM, Meulendijks D, Frederix GWJ, Kienhuis E, Creemers GJ, Baars A, Dezentjé VO, Imholz ALT, Jeurissen FJF, Portielje JEA, Jansen RLH, Hamberg P, Ten Tije AJ, Droogendijk HJ, Koopman M, Nieboer P, van de Poel MHW, Mandigers CMPW, Rosing H, Beijnen JH, Werkhoven EV, van Kuilenburg ABP, van Schaik RHN, Mathijssen RHJ, Swen JJ, Gelderblom H, Cats A, Guchelaar HJ, Schellens JHM.

Lancet Oncol. 2018 Nov;19(11):1459-1467. doi: 10.1016/S1470-2045(18)30686-7. Epub 2018 Oct 19.

PMID:
30348537
50.

Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Casali PG, Bielack S, Abecassis N, Aro HT, Bauer S, Biagini R, Bonvalot S, Boukovinas I, Bovee JVMG, Brennan B, Brodowicz T, Broto JM, Brugières L, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Dhooge C, Eriksson M, Fagioli F, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gaspar N, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Haas RL, Hassan B, Hecker-Nolting S, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kager L, Kasper B, Kopeckova K, Krákorová DA, Ladenstein R, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Morland B, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Strauss SJ, Sundby Hall K, Unk M, Van Coevorden F, van der Graaf WTA, Whelan J, Wardelmann E, Zaikova O, Blay JY; ESMO Guidelines Committee, PaedCan and ERN EURACAN.

Ann Oncol. 2018 Oct 1;29(Suppl 4):iv79-iv95. doi: 10.1093/annonc/mdy310. No abstract available.

Supplemental Content

Loading ...
Support Center